Candidiasis Clinical Trial
Official title:
Epidemiology of Invasive Candida Infections in Critically Ill Patients: A Multicenter, Prospective, Observational Study in China
The incidence of invasive candida infection (ICI) in critically ill patients is increasing day by day. The crude mortality of IFI in ICU could be as high as 25%-75% depending on their age, underlying conditions, and so on. Candida albicans was by far the predominant species in most countries, causing up to two thirds of all cases of invasive candidiasis. However, a shift toward non-albicans Candida species has been observed. Although the studies of ICI cause universal attention recently, there is still no large-scale, multi-center epidemiological research in China focusing on ICI in critically ill patients, therefore we conducted a large-scale multi-center observational study of IFI in critically ill patients named "China Scan" (CHINA Survey of Candidiasis in ICU) to assess the current incidence, mortality, pathogen spectrum, management, and risk factors for ICI in China ICUs.
Background of the study:
The incidence of invasive candida infection (ICI) in critically ill patients is increasing
day by day. The crude mortality of ICI in ICU could be as high as 25%-75% depending on their
age, underlying conditions, and so on. Candida albicans was by far the predominant species
in most countries, causing up to two thirds of all cases of invasive candidiasis. However, a
shift toward non-albicans Candida species has been observed. Although the studies of ICI
cause universal attention recently, there is still no large-scale, multi-center
epidemiological research in China focusing on IFI in critically ill patients, therefore we
conducted a large-scale multi-center observational study of IFI in critically ill patients
named "China Scan" (CHINA Survey of Candidiasis in ICU) to assess the current incidence,
mortality, pathogen spectrum, management, and risk factors for ICI in China ICUs.
Objective of the study:
Determine the current incidence of IFI in ICUs in China. Describe the risk factors for IFI
in China ICUs. Explore the pathogen spectrum of IFI in ICUs in China. Describe the in vitro
antifungal susceptibility of Candida isolates. Describe the antifungal treatment for ICU
patients with IFI. Evaluate in-hospital mortality among patients with IFI in ICUs.
;
Observational Model: Case-Only, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01982071 -
A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia
|
Phase 4 | |
| Completed |
NCT02391532 -
Effect of Probiotic Bacteria on Oral Candida in Frail Elderly
|
N/A | |
| Completed |
NCT01447407 -
Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine
|
Phase 1 | |
| Not yet recruiting |
NCT00889356 -
Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin and Ketoconazole for the Treatment of Mixed-Type Vaginosis, Bacterial Vaginosis and Candidiasis
|
Phase 3 | |
| Completed |
NCT00105144 -
Study of Micafungin in Patients With Invasive Candidiasis or Candidemia
|
Phase 3 | |
| Completed |
NCT00163111 -
A Clinical Study Intended To Compare Treatment With Voriconazole To Treatment With Amphotericin Followed By Fluconazole In Patients With Candidemia, A Serious Fungus Infection Of The Blood.
|
Phase 3 | |
| Completed |
NCT00138502 -
Funguria in Hospitalized Patients
|
||
| Not yet recruiting |
NCT04502277 -
Bioavailability of Flucanazole
|
Early Phase 1 | |
| Completed |
NCT03203551 -
Clinical and Laboratorial Evaluation of the Desinfection Solutions in Candida Species From Total Prostheses and Palate of Total Edentulous.
|
N/A | |
| Completed |
NCT05044156 -
Investigation of the Relationship Between Salivary Histatine-5 Level and Vaginal Candidiasis in Women
|
||
| Completed |
NCT01322698 -
Staging Candidiasis in ICU Patients
|
N/A | |
| Terminated |
NCT01092832 -
A Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients
|
Phase 3 | |
| Terminated |
NCT00095316 -
Caspofungin Study for Fungal Infections in Adults in Critical Care Settings
|
Phase 3 | |
| Completed |
NCT04122560 -
Fluconazole Pharmacokinetics, Including Bioavailability, in Obese Subjects After an Intravenous and Oral Administration
|
Phase 4 | |
| Completed |
NCT02641717 -
Validity of Patient-Collected Wet Mounts
|
N/A | |
| Completed |
NCT00734539 -
Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight
|
Phase 3 | |
| Completed |
NCT00797420 -
Pharmacokinetics (PK) Study of a Fluconazole Loading Dose in Infants and Toddlers
|
Phase 1 | |
| Completed |
NCT00001937 -
Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients
|
Phase 3 | |
| Completed |
NCT02666716 -
Pharmacokinetics of Fluconazole IV as Prophylaxis or Therapy to ICU Patients
|
||
| Terminated |
NCT00692783 -
Incidence of Oral Candidiasis, Prevalence of C. Dubliniensis in HIV Patients and In-vitro Azole Susceptibility
|
N/A |